drugset / Trial / NCT05533294

Study of ARO-RAGE in Healthy Subjects

NCT05533294 ↗

Phase 1 Completed 43 enrolled Arrowhead Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-RAGE Injection in normal healthy volunteers.

Timeline

Start
2022-11-29
Primary completion
2024-02-08
Completion
2024-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ARO-RAGE Unknown — Subcutaneous

Indications